NEW YORK (GenomeWeb News) – Progenika has joined the Personalized Medicine Coalition, a group that aims to promote policies that will benefit medicine aimed at diagnosing and treating disease and illness based on an individual’s unique genetic requirements.
Progenika, a US-based subsidiary of the European molecular diagnostics company Progenika Biopharma, is developing and marketing DNA tests designed to predict drug response and to help diagnose and predict disease.